Compare Microsoft (MSFT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs State Street SPDR S&P Biotech ETF — how do they compare? Microsoft trades at $534.86 (market cap $3.88T), while State Street SPDR S&P Biotech ETF trades at $154.06 (market cap $10.11B). The key difference: Microsoft is far larger — about 383.8× State Street SPDR S&P Biotech ETF's market cap, and Microsoft pays a 0.75% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Microsoft for 142 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| MSFT | XBI | |
|---|---|---|
Market Cap | $3.88T | $10.11B |
Volume | 19,593,392 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $542.07 | $169.55 |
52-Week Low | $352.83 | $104.99 |
Typical Hold Time | 142 Days | 37 Days |
Enterprise Value | $3.86T | — |
Dividend Yield | 0.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $534.75, up 0.94% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.74 surpassing the $4.24 expectation. Revenue grew to $281.72 billion in 2025, and net income reached $101.83 billion, reflecting a robust 40.31% net margin. Analysts maintain a strong buy consensus with an average price target of $571.76, indicating potential upside from current levels.
The outlook for Microsoft remains positive, driven by AI leadership, Azure cloud growth, and solid cash flow generation. Key opportunities include expanding AI services and cloud market share, while risks involve high capital expenditures, competitive pressures, and macroeconomic volatility. The stock's valuation multiples, such as a P/E of 29.11, are elevated but supported by earnings growth and market position.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
